BioCentury
ARTICLE | Distillery Therapeutics

Cancer

May 1, 2018 11:27 PM UTC

Studies in mice suggest dual inhibition of IRS1 and IRS2 could help treat KRAS-mutant NSCLC. In a mouse model of KRAS-mutant NSCLC, lung-specific dual knockout of IRS1 and IRS2 increased survival comp...